|3/4/2019||Orion Group Financial Statement documents 2018 and Corporate Governance Statement published|
|3/1/2019||Orion Corporation: Transfer of 47,279 own B shares on 1 March 2019|
|2/6/2019||The Board of Directors of Orion Corporation decided on an incentive plan for key persons|
|2/6/2019||Notice to the Annual General Meeting of Orion Corporation|
|3/8/2019||Darolutamide submitted for European marketing authorization|
|3/5/2019||Darolutamide submitted for marketing authorization in Japan|
|2/27/2019||The rolling submission to FDA for darolutamide in the U.S. completed|
|2/14/2019||Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial|
As the cost pressures on pharmaceutical companies increase, Orion needs to constantly improve its efficiency to stay competitive. In 2016, the company began a group-wide Lean program, where the entire staff is involved in a culture of continuous improvement. Orion’s shift toward Lean culture received the Lean Prize 2016 from Lean Association of Finland.
11 January 2017 | On 1st November 2016 the Innovative Medicines Initiative (IMI) together with an association of industrial partners came together to support PHAGO, an innovative research project devoted to the development of immunomodulatory therapies for Alzheimer’s disease (AD).